1. Home
  2. LGCB vs NRSN Comparison

LGCB vs NRSN Comparison

Compare LGCB & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LGCB

Linkage Global Inc

HOLD

Current Price

$1.78

Market Cap

23.4M

Sector

N/A

ML Signal

HOLD

Logo NeuroSense Therapeutics Ltd.

NRSN

NeuroSense Therapeutics Ltd.

HOLD

Current Price

$1.07

Market Cap

26.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGCB
NRSN
Founded
2011
2017
Country
Japan
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.4M
26.4M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
LGCB
NRSN
Price
$1.78
$1.07
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$14.00
AVG Volume (30 Days)
78.6K
281.7K
Earning Date
07-03-2025
04-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$8,993,265.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.80
N/A
52 Week Low
$1.22
$0.68
52 Week High
$6.83
$2.60

Technical Indicators

Market Signals
Indicator
LGCB
NRSN
Relative Strength Index (RSI) 45.82 62.58
Support Level $1.75 $0.81
Resistance Level $2.17 $0.90
Average True Range (ATR) 0.16 0.08
MACD 0.00 0.03
Stochastic Oscillator 29.17 92.86

Price Performance

Historical Comparison
LGCB
NRSN

About LGCB Linkage Global Inc

Linkage Global Inc is a cross-border e-commerce integrated service provider. It provides international e-commerce merchants, overseas brands, import and export trading enterprises, etc. with a globally selected supply chain, digital marketing, e-commerce training, international store, ERP and e-commerce software, social e-commerce and other e-commerce integrated services. The Company has two operating segments: Extend from Japan, and Other Subsidiaries from Hong Kong. The company is Committed to building a one-stop cross-border integrated service platform to make cross-border trade easier. Company operates in Japan, Hong Kong and China, with maximum revenue from Japan.

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Share on Social Networks: